For the year ending 2025-12-31, KYMR has $1,742,812K in assets. $163,148K in debts. $357,011K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 357,011 | |||
| Marketable securities (note 4) | 491,265 | |||
| Prepaid expenses and other current assets | 22,938 | |||
| Total current assets | 871,214 | |||
| Marketable securities, non-current (note 4) | 771,158 | |||
| Property and equipment, net (note 6) | 43,175 | |||
| Right-of-use assets, operating leases | 42,351 | |||
| Other non-current assets | 9,114 | |||
| Restricted cash | 5,800 | |||
| Total assets | 1,742,812 | |||
| Accounts payable | 4,015 | |||
| Accrued expenses (note 8) | 42,274 | |||
| Deferred revenue | 22,925 | |||
| Operating lease liabilities | 11,941 | |||
| Finance lease liabilities | 1,815 | |||
| Other current liabilities | 242 | |||
| Total current liabilities | 83,212 | |||
| Deferred revenue, net of current portion | 11,440 | |||
| Operating lease liabilities, net of current portion | 67,034 | |||
| Finance lease liabilities, net of current portion | 1,462 | |||
| Total liabilities | 163,148 | |||
| Common stock, 0.0001 par value 150,000,000 shares authorized at december 31, 2025 and 2024, 81,323,532 and 64,890,193 shares issued and outstanding at december 31, 2025 and 2024, respectively | 8 | |||
| Additional paid-in capital | 2,643,817 | |||
| Accumulated deficit | -1,065,961 | |||
| Accumulated other comprehensive income (loss) | 1,800 | |||
| Total stockholders' equity | 1,579,664 | |||
| Total liabilities and stockholders' equity | 1,742,812 | |||
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)